MD/PHD PROFILE
Eric Wolhford

Eric Wohlford

Eric studied the effects of malaria on B cells in Kenya.  View more...

Faculty

David B Duggan, MD

David B Duggan, MD
Appointed 08/15/85
2272 Campus West Building (CWB)
750 East Adams Street
Syracuse, NY 13210

315 464-8668

Current Appointments

  • Professor of Medicine
  • Dean, College of Medicine

Hospital Campus

  • Downtown

Clinical Section Affiliations

  • Medicine: Hematology and Oncology
  • Upstate Cancer Center: Medical Oncology

Research Programs and Affiliations

  • Medicine

Clinic/Unit

Education & Fellowships

  • Fellowship: Tufts-New England Medical Center, 1985, Hematology-Oncology
  • Residency: Tufts-New England Medical Center, 1982, Internal Medicine
  • MD: SUNY Health Science Center at Syracuse, 1979
  • BA: Hamilton College, 1975, Biology

Research Interests

  • Clinical trials in cancer; Breast Cancer; Hodgkin's Disease, Lymphoma and  Leukemia.

Specialties & Certification

  • Internal Medicine
  • Hematology
  • Oncology
  • Medical Oncology

Diseases & Conditions Treated

  • Adult Leukemia
  • Adult Lymphoma
  • All Cancers and Hematological Conditions
  • Breast Cancer
  • Hodgkin's Lymphoma

Treats

  • Adults

Treatments/Services

  • Blood Transfusion
  • Bone Marrow Aspiration
  • Bone Marrow Biopsy
  • Chemotherapy
  • Infusional Therapies
  • Lumbar Puncture
  • Paracentesis
  • Thoracentesis

Associations/Memberships

  • American College of Physicians (ACP)
  • American Society of Clinical Oncology - ASCO
  • American Society of Hematology (ASH)

Current Hospital Privileges

  • Upstate University Hospital

Publications

Link to PubMed External Icon (Opens new window. Close the PubMed window to return to this page.)

Research

Selected References

Parnes HL, Cirrincione C, Aisner J, Berry DA, Allen SL, Abrams J, Chuang E, Cooper MR, Perry MC, Duggan DB, Szatrowski TP, Henderson IC, Norton L. Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140. J Clin Oncol. 2003 May 1;21(9):1819-24.

Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, Ingle JN, Cooper MR, Hayes DF, Tkaczuk KH, Fleming G, Holland JF, Duggan DB, Carpenter JT, Frei E 3rd, Schilsky RL, Wood WC, Muss HB, Norton L. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003 Mar 15;21(6):976-83.

Duggan DB, Petroni GR, Johnson JL, Glick JH, Fisher RI, Connors JM, Canellos GP, Peterson BA. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol. 2003 Feb 15;21(4):607-14.

Hayes DF, Yamauchi H, Broadwater G, Cirrincione CT, Rodrigue SP, Berry DA, Younger J, Panasci LL, Millard F, Duggan DB, Norton L, Henderson IC. (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662.Clin Cancer Res. 2001 Sep;7(9):2703-1

Clinical Profile Shortcut: http://www.upstate.edu/findadoc/duggand
Faculty Profile Shortcut: http://www.upstate.edu/faculty/duggand